Financing Obligations - Additional Information (Detail) - USD ($)			1 Months Ended					3 Months Ended					12 Months Ended
	Mar. 21, 2016	Sep. 28, 2015	Mar. 23, 2016	Feb. 29, 2016	Mar. 31, 2014	Feb. 28, 2011	Jun. 30, 2010	Dec. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	May. 31, 2013
Debt Instrument [Line Items]
Common stock shares issued								19,577,729					19,577,729	19,404,697
Proceeds from financing obligations													$ 2,914,000	$ 50,830,000	$ 15,000,000
Aggregate annual net sales of ADASUVE and Staccato enabled products													2,355,000	2,564,000	874,000
Non-recourse notes issued					$ 45,000,000								$ 45,000,000
Warrants to purchase common stock					345,661			345,661		345,661			345,661
Price of common stock per share					$ 0.01					$ 0.01
Warrant exercisable term					5 years
First quarterly interest payment													Jun. 15, 2014
Interest reserve					$ 6,890,000					$ 6,890,000				2,757,000
Expected volatility rate					87.00%
Estimated life of the warrant					5 years								5 years
Risk-free interest rate					1.54%
Expected dividend yield					0.00%
Value of warrants issued with royalty securitization financing					$ 1,721,000					1,721,000				1,721,000
Interest expense amortization period					5 years			5 years					5 years
Total fees and expenses					$ 4,171,000
Payment of interest in debt instrument								$ 0
Default interest payable								$ 2,800,000					$ 2,800,000
Renewal period								30 days
Amortization of debt discount								$ 74,000
Common stock value of shares issued								2,000					2,000	2,000
Financing from royalty securitization								$ 45,000,000					$ 45,000,000
Royalty securitization financing legal maturity date													2027
Ferrer Note [Member]
Debt Instrument [Line Items]
Promissory note, due date		May 31, 2016
Debt instrument interest rate		6.00%
Common stock shares issued		125,000
Proceeds from financing obligations		$ 3,000,000
Additional tranche to borrow																$ 1,000,000
Debt instrument, effective interest rate		10.50%
Percentage of common stock issued recorded as discount to promissory notes		60.00%
Percentage of common stock issued capitalized		40.00%
Common stock value of shares issued		$ 144,000
Ferrer Note [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Proceeds from financing obligations	$ 1,000,000		$ 1,000,000
Principal amount of the Ferrer Note outstanding			$ 4,000,000
Ferrer Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Principal amount of promissory note																$ 5,000,000
Ferrer Promissory Note Tranche Two [Member]
Debt Instrument [Line Items]
Promissory note, due date		May 31, 2016
Ferrer Promissory Note Tranche Two [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Proceeds from financing obligations	$ 1,000,000
Autoliv ASP, Inc. [Member]
Debt Instrument [Line Items]
Amount of cash paid to Autoliv ASP, Inc.							$ 4,000,000
Value of cancelled note						$ 4,000,000
Autoliv ASP, Inc. [Member] | Original Note [Member]
Debt Instrument [Line Items]
Value of unsecured promissory note issued							$ 4,000,000
Autoliv ASP, Inc. [Member] | New Note [Member]
Debt Instrument [Line Items]
Debt instrument interest rate						8.00%
Value of unsecured promissory note issued						$ 2,800,000
Installment period of New Note						48 months
Periodic payment of New Note						$ 68,000
Teva Pharmaceuticals USA, Inc. [Member]
Debt Instrument [Line Items]
Debt instrument interest rate																	400.00%
Proceeds from financing obligations									$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 10,000,000		25,000,000
Debt instrument payment terms													At any time prior to five days before the maturity date, Teva has the right to convert the then outstanding amounts into shares of our common stock at a conversion price of $4.4833 per share.
Debt instrument conversion price per share																	$ 4.4833
Interest expense under right-to-borrow asset														$ 216,000	$ 752,000
Debt instrument, effective interest rate					11.60%				6.60%	11.60%	10.20%	14.20%			10.20%
Teva Note [Member]
Debt Instrument [Line Items]
Debt instrument, effective interest rate					12.25%					12.25%
Notes redemption description													The Notes have no other recourse to us. The Notes may not be redeemed at our option until after March 18, 2016, and may be redeemed after that date subject to the achievement of certain milestones and the payment of a redemption premium for any redemption occurring prior to March 19, 2019.
Teva Note [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Periodic payment of New Note				$ 5,000,000
Common stock issued for reduction in outstanding balance of Notes				2,172,886
Reduction in outstanding balance of Notes				$ 5,000,000
Outstanding balance of Notes				$ 20,000,000
Frequency of periodic payment				Four
Aggregate annual net sales of ADASUVE and Staccato enabled products				$ 50,000,000